Citius Oncology, Inc.

1.7500+0.01 (+0.58%)

Oct 29, 4:00:01 PM EDT · NasdaqCM · CTOR · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

146.15M

P/E (TTM)

Basic EPS (TTM)

-0.39

Dividend Yield

Recent Filings

8-K

10/23/25Oct 23, 2025

8-K

9/10/25Sep 10, 2025

8-K

8/18/25Aug 18, 2025

10-Q

8/12/25Aug 12, 2025

8-K

8/12/25Aug 12, 2025

About

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

CEO

Mr. Leonard L. Mazur

IPO

12/8/2022

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic